Dual layer mesh stents constitute a novel treatment option for patients who undergo carotid artery stenting (CAS). The aim of this prospective study is to report 12 month outcomes of patients who underwent CAS with CGuard (Inspire MD, Tel Aviv, Israel) microNET self-expanding stent with embolic protection system in a tertiary center from October 2018 to March 2022. Primary endpoints included in-stent restenosis >70% verified by ultrasound (DUS), ipsilateral transient ischemic attack (TIA), and stroke at 12 months. Secondary endpoints included cardiovascular-related mortality (stroke, myocardial infarction, heart failure) and all-cause mortality during follow-up. One hundred thirteen patients were included in the study (male 72.5%), symptomatic 47.8%. Median follow-up was 25 months (2-48). By 12 months, there was one in-stent occlusion that manifested as stroke (1/113, 0.8%) but no other forms of in-stent restenosis. Two patients experienced contralateral TIA (1.7%). CVRM was 3.5% (4 MI) and all-cause mortality was 6% at follow-up. This prospective study shows that CAS with CGuard MicroNET-covered stent is safe with minimal neurological adverse events at 12 months follow-up. Larger, and longer-term studies are necessary to define CGuard long-term safety and protection against carotid-related stroke.

中文翻译：

---

使用 CGuard MicroNET 覆盖支架进行颈动脉支架置入术的 12 个月结果：一项针对 113 名患者的单中心研究。

双层网状支架为接受颈动脉支架置入术 (CAS) 的患者提供了一种新的治疗选择。这项前瞻性研究的目的是报告 2018 年 10 月至 2022 年 3 月在三级中心使用 CGuard（Inspire MD，以色列特拉维夫）带有栓塞保护系统的 microNET 自膨胀支架接受 CAS 的患者的 12 个月结果。 主要终点包括经超声 (DUS) 验证的支架内再狭窄 >70%、同侧短暂性脑缺血发作 (TIA) 和 12 个月时的卒中。次要终点包括心血管相关死亡率（中风、心肌梗塞、心力衰竭）和随访期间的全因死亡率。该研究纳入了 113 名患者（男性 72.5%），有症状的 47.8%。中位随访时间为 25 个月 (2-48)。到 12 个月时，出现 1 例支架内闭塞，表现为中风（1/113，0.8%），但没有其他形式的支架内再狭窄。两名患者经历了对侧 TIA（1.7%）。随访时 CVRM 为 3.5% (4 MI)，全因死亡率为 6%。这项前瞻性研究表明，采用 CGuard MicroNET 覆盖支架的 CAS 是安全的，在 12 个月的随访中神经系统不良事件极少。需要进行更大规模、更长期的研究来确定 CGuard 的长期安全性和针对颈动脉相关中风的保护作用。